ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Advanced Magnetics' Ferumoxytol Data Monitoring Committee Identifies No Safety Concerns
Advanced Magnetics
(Amex: AVM) today announced that the independent Data Monitoring Committee
(DMC) providing oversight for the ferumoxytol Phase III iron replacement
therapy program met and informed the company that it has carefully reviewed
the cumulative safety data from the ferumoxytol Phase III studies and
identified no safety concerns. The DMC also recommended the continuation of
the ferumoxytol Phase III studies with no modifications.
Ferumoxytol, the key product in the company's development pipeline, is
in Phase III multi-center clinical trials for use as an intravenous (IV)
iron replacement therapeutic in chronic kidney disease patients, whether or
not on dialysis.
"We are pleased with the continued recommendations from the DMC
regarding our Phase III development program for ferumoxytol," stated Brian
J.G. Pereira, MD, President of Advanced Magnetics. "We are encouraged by
its report to us and remain committed to the successful completion of our
Phase III development program."
Advanced Magnetics announced the formation of the DMC in August of 2005
to provide independent oversight of the company's development program for
ferumoxytol as an IV iron replacement therapeutic in chronic kidney disease
patients, whether or not on dialysis. The DMC has also met to review
cumulative safety data in October 2005 and February 2006. At both of these
meetings, the DMC identified no safety concerns and recommended the
continuation of the Phase III studies with no modifications. At all
meetings, the DMC has available to it data on adverse events, serious
adverse events and patient disposition.
About Advanced Magnetics
Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products. As a leader in our field, we
are dedicated to the development and commercialization of our proprietary
nanoparticle technology for use in therapeutic iron compounds to treat
anemia, as well as novel imaging agents to aid in the diagnosis of cancer
and cardiovascular disease. For more information about us, please visit our
website at http://www.advancedmagnetics.com, the content of which is not
part of this press release.
This document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and federal securities
laws. Any statements contained in this press release that do not describe
historical facts, including but not limited to, statements regarding our
commitment to the successful completion of our Phase III development
program, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from
those discussed in such forward-looking statements. Such risks and
uncertainties include the following: (1) the possibility that we may not be
able to successfully complete the clinical development of ferumoxytol, or
may not be able to complete the development in a timely or cost-effective
manner, due to the timing of enrollment of patients in the Phase III
studies, unexpected results from our clinical sites, inadequate performance
by third-party service providers involved in the conduct of the clinical
trials, deficiencies in the design or oversight by us of these trials, or
any other factor causing an increase in expenses, a delay and/or a negative
effect on the results of the clinical studies for ferumoxytol; (2)
uncertainties surrounding the timing and results of FDA interactions
regarding the clinical development of ferumoxytol and our ability to obtain
regulatory approval for ferumoxytol from the FDA; (3) the possibility that
the results of past ferumoxytol studies may not be replicated in future
studies; (4) the possibility that we may not be able to raise additional
capital on terms and on a timeframe acceptable to us, if at all; (5)
uncertainties relating to our patents and proprietary rights; and (6) other
risks identified in our Securities and Exchange Commission filings. We
caution readers not to place undue reliance on any forward-looking
statements which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to reflect any
change in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking
statements.
Advanced Magnetics
http://www.advancedmagnetics.com
Advanced Magnetics "Comitetul de monitorizare a datelor Ferumoxytol Identificã nr siguranþã - Advanced Magnetics' Ferumoxytol Data Monitoring Committee Identifies No Safety Concerns - articole medicale engleza - startsanatate